New Approaches to Pulmonary Hypertension
- 15 March 2001
- journal article
- review article
- Published by Taylor & Francis in Hospital Practice
- Vol. 36 (3) , 29-40
- https://doi.org/10.3810/hp.2001.03.231
Abstract
Careful evaluation will often reveal secondary--and perhaps reversible--factors contributing to pulmonary hypertension. For primary disease, there are now a variety of treatments, ranging from calcium channel blockers to lung transplantation.Keywords
This publication has 6 references indexed in Scilit:
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- Appetite-Suppressant Drugs and the Risk of Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.Circulation, 1987
- Pulmonary Hypertensive DiseasesChest, 1984